Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioharvest Sciences (BHST) Depreciation & Amortization (CF) (2023 - 2025)

Bioharvest Sciences has reported Depreciation & Amortization (CF) over the past 3 years, most recently at $433000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 26.98% year-over-year to $433000.0; the TTM value through Dec 2025 reached $1.6 million, up 29.82%, while the annual FY2025 figure was $1.6 million, 29.82% up from the prior year.
  • Depreciation & Amortization (CF) was $433000.0 for Q4 2025 at Bioharvest Sciences, up from $385000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $433000.0 in Q4 2025 and bottomed at $202000.0 in Q1 2024.
  • The 3-year median for Depreciation & Amortization (CF) is $354000.0 (2024), against an average of $330800.0.
  • The widest YoY moves for Depreciation & Amortization (CF): up 97.52% in 2025, down 9.69% in 2025.
  • Over 3 years, Depreciation & Amortization (CF) stood at $216000.0 in 2023, then surged by 57.87% to $341000.0 in 2024, then rose by 26.98% to $433000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $433000.0 (Q4 2025), $385000.0 (Q3 2025), and $407000.0 (Q2 2025) per Business Quant data.